Breakable Organosilica Nanocapsules for the Intracellular Delivery of a Peptide With Promising Anti‐Breast Cancer Activity
ChemistryEurope · 2026-07 · 4 (7)
DOI: 10.1002/ceur.70336 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistryEurope, online erschienen am 21.07.2026. Verfasst von Sara Mathlouthi und 8 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
High‐mobility group box 1 (HMGB1) is a protein acting as a regulator in tumor progression and therapy resistance, including breast cancer. HBP08‐2, a novel HMGB1‐inhibiting peptide, showed promising therapeutic potential; however, its poor stability and susceptibility to degradation limit cellular uptake. To overcome these limitations, a nanotechnology‐based delivery system was developed using breakable organosilica nanocapsules designed to degrade under reducing intracellular conditions. Nanocapsules were synthesized through a microemulsion‐assisted Stöber method and characterized by dynamic light scattering, transmission electron microscopy, and peptide quantification. They exhibited an encapsulation efficiency of 15.6%, a peptide content of 0.031 mg per mg of nanocapsules, and an average diameter of about 60 nm. In vitro studies demonstrated efficient internalization in MCF‐7 and MDA‐MB‐231 breast cancer cells, with >99% sulfo‐Cy5‐positive cells after 3 and 6 h. Empty nanocapsules were nontoxic and biocompatible, while HBP08‐2‐loaded nanocapsules reduced cell viability by approximately 30% after 96 h. Coadministration with paclitaxel (PTX), a first‐line chemotherapeutic, further enhanced the effect, reducing viability by up to 46.0% in MCF‐7 and 43.4% in MDA‐MB‐231, suggesting that the combination of HBP08‐2@CAPS and PTX may enhance cytotoxic activity compared with individual treatments. These findings support nanocapsules as a safe and versatile platform for intracellular peptide delivery and HMGB1‐targeted strategies.
Zitieren
APA
Mathlouthi, S., Ajò, A., Fassi, E. M. A., Cagnotto, A., Fragassi, A., Pesce, C., Garofalo, M., Cola, L. D., & Grazioso, G. (2026). Breakable Organosilica Nanocapsules for the Intracellular Delivery of a Peptide With Promising Anti‐Breast Cancer Activity. ChemistryEurope, 4(7). https://doi.org/10.1002/ceur.70336
Vancouver
Mathlouthi S, Ajò A, Fassi EMA, Cagnotto A, Fragassi A, Pesce C, et al. Breakable Organosilica Nanocapsules for the Intracellular Delivery of a Peptide With Promising Anti‐Breast Cancer Activity. ChemistryEurope. 2026;4(7). doi:10.1002/ceur.70336
BibTeX
@article{Mathlouthi2026,
author = {Mathlouthi, Sara and Ajò, Alessandro and Fassi, Enrico Mario Alessandro and Cagnotto, Alfredo and Fragassi, Agnese and Pesce, Cristiano and Garofalo, Mariangela and Cola, Luisa De and Grazioso, Giovanni},
title = {Breakable Organosilica Nanocapsules for the Intracellular Delivery of a Peptide With Promising Anti‐Breast Cancer Activity},
journal = {ChemistryEurope},
year = {2026},
volume = {4},
number = {7},
doi = {10.1002/ceur.70336}
}
EUVIMED